4-[4-(3-phenylpropyl)piperazin-1-yl]-2-[(1S)-1-(1,3-thiazol-2-yl)ethyl]isoindole-1,3-dione
C26H28N4O2S — CID 26351747
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[4-(3-phenylpropyl)piperazin-1-yl]-2-[(1S)-1-(1,3-thiazol-2-yl)ethyl]isoindole-1,3-dione
4-[4-(3-phenylpropyl)piperazin-1-yl]-2-[(1S)-1-(1,3-thiazol-2-yl)ethyl]isoindole-1,3-dione (PubChem CID 26351747) has the molecular formula C26H28N4O2S and a molecular weight of 460.60 g/mol. Its IUPAC name is 4-[4-(3-phenylpropyl)piperazin-1-yl]-2-[(1S)-1-(1,3-thiazol-2-yl)ethyl]isoindole-1,3-dione.
Molecular Properties
| Compound Name | 4-[4-(3-phenylpropyl)piperazin-1-yl]-2-[(1S)-1-(1,3-thiazol-2-yl)ethyl]isoindole-1,3-dione |
|---|---|
| PubChem CID | 26351747 |
| Molecular Formula | C26H28N4O2S |
| Molecular Weight | 460.60 g/mol |
| Exact Mass | 460.19 |
| IUPAC Name | 4-[4-(3-phenylpropyl)piperazin-1-yl]-2-[(1S)-1-(1,3-thiazol-2-yl)ethyl]isoindole-1,3-dione |
| SMILES | C[C@@H](c1nccs1)N1C(=O)c2cccc(N3CCN(CCCc4ccccc4)CC3)c2C1=O |
| InChI | InChI=1S/C26H28N4O2S/c1-19(24-27-12-18-33-24)30-25(31)21-10-5-11-22(23(21)26(30)32)29-16-14-28(15-17-29)13-6-9-20-7-3-2-4-8-20/h2-5,7-8,10-12,18-19H,6,9,13-17H2,1H3/t19-/m0/s1 |
| InChIKey | MSFKGLIREBQZPC-IBGZPJMESA-N |
| XLogP | 4.26 |
| TPSA | 56.75 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 460.60 |
| LogP ≤ 5 | 4.26 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'phthalimide', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 26351747 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.